Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp is poised for a favorable financial outlook, highlighted by its expected FY25 operating margin increase to approximately 24%, reflecting strong operational efficiency. The company demonstrated significant growth with a gross margin improvement of 240 basis points year-over-year and a 390 basis points increase in operating margin, indicating effective cost management and revenue generation. Notably, the plasma segment showed robust revenue growth driven by premium pricing and growth in collections, while the transfusion management segment also experienced double-digit growth, suggesting strong demand and market expansion.

Haemonetics Corporation has demonstrated declining sales in several key segments, with Blood Center sales decreasing 2.8% to $68.5 million and plasma sales falling 9.1% to $138.6 million, both reflecting weaker performance than anticipated. Additionally, the company has lowered its growth expectations for both the hospital and blood center segments, projecting organic Hospital growth of 12-14%—a reduction from the previous forecast of 14-17%—and Blood Center growth to decline between 5-7%. The overall organic revenue growth has significantly slowed to a negative 0.3% in F3Q25, indicating potential challenges ahead, including expected worse-than-forecast operating margins and earnings below market consensus.